专利检索_ .与一个氧原子结合专利检索_ .与一个氧原子结合专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
1	cAMPのためのルシフェラーゼバイオセンサー	JP2014266438	2014-12-26	JP6275635B2	2018-02-07	ビンコウスキーブロック; エンセルランスピー; ウッドモニカジー; ウッドキースヴィー; ツィンマーマンクリス; オットーポール; ヴィデュギリスゲディミナス; ステーシャピート

2	エビルシフェラーゼの触媒蛋白質の変異遺伝子とその使用法	JP2014084499	2014-04-16	JP2015202096A	2015-11-16	井上敏; 三浦由依子; 佐藤淳一
【課題】深海エビであるオプロフォーラス(Oplophorus gracilirostris)由来のルシフェラーゼの細胞外への分泌型の新規変異体の提供。【解決手段】オプロフォーラスルシフェラーゼにおいて発光を触媒する分子量19kDa蛋白質の既知の変異体(nanoKAZ)の変異部位について検証をおこない、変異の選択及び組合せによりセレンテラジンを発光基質としてより活性が高く、動物培養細胞内で発現したときに真核細胞生物由来の分泌シグナル配列の有無にかかわらず細胞外へ分泌するルシフェラーゼ変異体。【選択図】なし
3	MODIFIED POLYNUCLEOTIDES FOR ALTERING CELL PHENOTYPE	EP13863551	2013-12-12	EP2931914A4	2016-08-17	BANCEL STEPHANE; DE FOUGEROLLES ANTONIN; WHORISKEY SUSAN; CHAKRABORTY TIRTHA; HUANG ERIC YI-CHUN
The present invention relates to compositions, methods and kits using cell phenotype altering polynucleotides, cell phenotype altering primary transcripts and cell phenotype altering mmRNA molecules.
4	LUCIFERASE BIOSENSORS FOR cAMP	EP09750966.5	2009-05-19	EP2281046B1	2012-01-25	ENCELL, Lance, P.; ZIMMERMAN, Kris; OTTO, Paul; VIDUGIRIS, Gediminas; STECHA, Pete; BINKOWSKI, Brock; WOOD, Monika, G.; WOOD, Keith, V.
A modified luciferase protein which is a sensor for molecules including cAMP is provided. The modified luciferase protein includes one or more heterologous amino acid sequences, at least one of which directly or indirectly interacts with cAMP.
5	MEANS AND METHODS FOR DETERMINING NEUROTOXIN ACTIVITY BASED ON A MODIFIED LUCIFERASE	EP13707663.4	2013-03-07	EP2823053B1	2017-08-23	EISELE, Karl-Heinz

6	A CPG-free gene for a new secreted reporter protein	EP13305057.5	2013-01-18	EP2617813B1	2015-01-14	Reynes, Jean-Paul; Casteran, Céline; Drocourt, Daniel; Tiraby, Gérard

7	HIGH-THROUGHPUT SPLIT APTAMER SCREENING ASSAY	US15756851	2016-09-07	US20180251765A1	2018-09-06	Meera Kumar; Robert G. Lowery
Methods and materials for development of high-throughput screening assays using split aptamers are provided by this invention.
8	MUTATED GENES FOR THE CATALYTIC PROTEIN OF OPLOPHORUS LUCIFERASE AND USE THEREOF	US15834147	2017-12-07	US20180119112A1	2018-05-03	Satoshi INOUYE; Yuiko MIURA; Junichi SATO
A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
9	DESIGN METHOD FOR SYNTHETIC GENES	US14848535	2015-09-09	US20160076052A1	2016-03-17	Satoshi INOUYE
The present invention provides a method of designing an optimized gene which comprises altering a nucleotide sequence of a target protein gene, so that only preferential codons with high frequency of use in human cells are selected and a GC content of not less than 60% is achieved. A gene design method which involves the feature “only preferential codons with high frequency of use are selected and a GC content of not less than 60% is achieved” can be established as a general rule for preparing proteins with high expression level, in order to obtain chemically synthesized genes for proteins capable of high-level expression in eukaryotes.
10	Method of screening a drug such as insulin secretagogue	US12659604	2010-03-15	US09181318B2	2015-11-10	Inouye Satoshi
The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.
11	CPG-free gene for a new secreted reporter protein	US13354469	2012-01-20	US08435777B1	2013-05-07	Jean Paul Reynes; Céline Casteran; Daniel Drocourt; Gérard Tiraby
A synthetic gene devoid of CpG nucleotide derived by genetic engineering from copepod luciferases genes that code for a new secreted luciferase with a strong bioluminescent signal. This gene display advantageous properties to be used as a reporter genes in cell based assays.
12	Method of screening a drug such as insulin secretagogue	US12659604	2010-03-15	US20100240038A1	2010-09-23	Satoshi Inouye
The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.
13	NANOBODY CONJUGATES AND PROTEIN FUSIONS AS BIOANALYTICAL REAGENTS	US15891981	2018-02-08	US20180224459A1	2018-08-09	Brian R. McNaughton; Virginia J. Bruce
Systems and methods for detecting a target protein using a nanobody-peptide receptor pair are described.
14	Mutated genes for the catalytic protein of oplophorus luciferase and use thereof	US14685643	2015-04-14	US09868941B2	2018-01-16	Satoshi Inouye; Yuiko Miura; Junichi Sato
A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
15	Method of screening a drug such as insulin secretagogue	US14868948	2015-09-29	US09835615B2	2017-12-05	Satoshi Inouye
The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.
16	METHOD OF SCREENING A DRUG SUCH AS INSULIN SECRETAGOGUE	US14868948	2015-09-29	US20160011173A1	2016-01-14	Satoshi INOUYE
The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.
17	MUTATED GENES FOR THE CATALYTIC PROTEIN OF OPLOPHORUS LUCIFERASE AND USE THEREOF	US14685643	2015-04-14	US20150299675A1	2015-10-22	Satoshi INOUYE; Yuiko MIURA; Junichi SATO
A novel luciferase that is distinct from conventional luciferase has been desired. A luciferase mutant comprising an amino acid sequence in which glutamic acid at position 4, arginine at position 11, leucine at position 18 and valine at position 27 are substituted with other amino acids, in the amino acid sequence of SEQ ID NO: 2.
18	MEANS AND METHODS FOR DETERMINING NEUROTOXIN ACTIVITY BASED ON A MODIFIED LUCIFERASE	US14382929	2013-03-07	US20150044709A1	2015-02-12	Karl-Heinz Eisele
The present invention is concerned with test systems for determining the activity of neurotoxin polypeptides. Specifically, it relates to a polynucleotide encoding a single chain luciferase fusion polypeptide comprising: (i) a LuxB subunit, (ii) a linker comprising a neurotoxin cleavage site, and (iii) a LuxA subunit and a polypeptide encoded by the polynucleotide. Further provided in accordance with the invention are a vector and a host cell comprising the polynucleotide. Moreover, the present invention relates to a method for determining a proteolytically active neurotoxin polypeptide in a sample and a kit for carrying out the method.
19	LIGHT-EMITTING MOLECULES	US13990250	2011-12-05	US20130273582A1	2013-10-17	John Daly; Leon Michael Brownrigg; Jim Yu-Hsiang Tiao
Disclosed are luciferase polypeptides with improved light-emitting activity and their encoding nucleic acids. These molecules are useful in a range of assays including luciferase-based gene reporter assays, bioluminescence resonance energy transfer assays, protein complementation assays and other applications in which luciferase enzymes are utilized as detectable and/or quantifiable labels. Also disclosed are methods and compositions for increasing the sensitivity and/or improving the kinetics of luciferase-catalyzed reactions as well as decreasing the impact of undesirable variables.
20	cAMPのためのルシフェラーゼバイオセンサー	JP2014266438	2014-12-26	JP2015091253A	2015-05-14	ビンコウスキーブロック; エンセルランスピー; ウッドモニカジー; ウッドキースヴィー; ツィンマーマンクリス; オットーポール; ヴィデュギリスゲディミナス; ステーシャピート
【課題】cAMPを含む分子のセンサーである修飾ルシフェラーゼタンパク質を提供する。【解決手段】修飾ルシフェラーゼタンパク質は、そのうちの少なくとも1つが直接または間接にcAMPと相互作用する1以上の異種アミノ酸配列を含み、修飾ルシフェラーゼにおけるcAMP結合部位とサイクリックヌクレオチド等の目的とする分子との間の相互作用を調節する薬剤、サイクリックヌクレオチドの存在若しくは量を調節する薬剤、又は細胞内サイクリックヌクレオチド濃度と関連する受容体等の分子を調節する薬剤を有するポリヌクレオチド。【選択図】図7A

1 2 3

该功能需要专业版企业版VIP权限，您可以：